Nadia D. Ali, MD, is eager to attend the upcoming 2024 ASH Annual Meeting and Exposition, particularly for sessions on nonmalignant hematology, focusing on red blood cells, erythropoiesis, and hemoglobinopathies like sickle cell disease and thalassemia. Dr Ali is especially interested in updates on gene therapy, patient counseling, and the development of new drugs to regulate hematopoiesis for conditions such as anemia and myelodysplastic syndromes.
A noted highlight is an oral abstract on etavopivat, a drug showing promise in improving oxygen saturation during hypoxia in healthy volunteers, which may also benefit patients with anemia in conditions like chronic renal disease. Finally, Dr Ali is curious about news on the use of AI in hematology to analyze large datasets and improve patient outcomes in clinical practice.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASH 2024: A Glimpse of Exciting Developments in Red Blood Cell Disorders - Medscape - Nov 25, 2024.
Comments